Quest Diagnostics Adds Former Walgreens CEO Tim Wentworth to Board
Quest Diagnostics Incorporated (NYSE: DGX) has elected Timothy Wentworth, the former chief executive officer of Walgreens Boots Alliance, to its board of directors, according to an SEC filing on March 12, 2026.
The Change
The election of Wentworth to Quest's board took place on March 9, 2026, following a recommendation from the board's Governance Committee. The company's board determined that Wentworth qualifies as an independent director under both New York Stock Exchange listing standards and Quest's own independence guidelines.
Wentworth will serve on two key board committees: the Compensation and Leadership Development Committee and the Quality and Compliance Committee. These appointments position him to influence both executive compensation decisions and the company's quality standards and regulatory compliance efforts.
As part of his compensation package as a non-employee director, Wentworth received a prorated one-time grant of restricted share units valued at approximately $43,000 upon joining the board. He will receive ongoing compensation in accordance with the company's standard non-employee director compensation practices.
Background
Wentworth brings significant healthcare industry experience to Quest Diagnostics, having served as chief executive officer of Walgreens Boots Alliance, one of the largest pharmacy chains in the United States. His background in retail pharmacy and healthcare services provides Quest with valuable perspective as the diagnostic testing industry continues to evolve.
Quest Diagnostics, headquartered in Secaucus, New Jersey, is one of the nation's leading providers of diagnostic information services. The company operates a network of laboratories and patient service centers throughout the United States, serving approximately half of the physicians and hospitals in the country.
The addition of Wentworth comes at a time when the diagnostic testing industry faces ongoing changes in healthcare delivery models, including the growth of direct-to-consumer testing, telehealth integration, and value-based care arrangements. His experience leading a major healthcare retail organization could prove valuable as Quest navigates these industry shifts.
What It Means
Wentworth's appointment to Quest's board signals the company's interest in leveraging retail healthcare expertise as the diagnostic testing industry becomes increasingly consumer-focused. His experience at Walgreens Boots Alliance, which operates thousands of retail locations offering various healthcare services, could help Quest explore new patient access strategies and service delivery models.
The decision to place Wentworth on both the Compensation and Leadership Development Committee and the Quality and Compliance Committee suggests Quest values his operational experience in managing large-scale healthcare operations. The Quality and Compliance Committee appointment is particularly notable given the critical importance of regulatory compliance in the diagnostic testing industry.
For investors, this board addition represents Quest's commitment to bringing diverse healthcare perspectives to its governance structure. Wentworth's retail pharmacy background complements the existing board expertise and could influence strategic decisions around patient convenience, accessibility, and the integration of diagnostic services with broader healthcare delivery networks.
The timing of this appointment, coming in early 2026, positions Wentworth to contribute to Quest's strategic planning as the company continues to adapt to post-pandemic healthcare trends and evolving patient expectations for diagnostic services. His fresh perspective from the retail pharmacy sector may help Quest identify new growth opportunities and operational efficiencies.
This board election reflects a broader trend of healthcare companies seeking directors with cross-sector experience as traditional boundaries between different healthcare segments continue to blur. As diagnostic testing becomes more integrated with pharmacy services, telehealth, and retail health clinics, Wentworth's background positions him to provide valuable insights on these convergence opportunities.
*Source: Quest Diagnostics Form 8-K filed with the Securities and Exchange Commission on March 12, 2026*
*StockCliff Research*